Long-term Follow-up for CGT Webinar
Long-term follow-up considerations for cell and gene therapies
In this webinar, a panel of experts will cover key regulatory, operational, medical and scientific insights when considering long-term follow-up (LTFU) studies in the cell and gene therapy (CGT) space.
While both cell and gene therapies offer long-term benefits for patients, safety and efficacy must be thoroughly evaluated before widespread clinical use, as with any emerging medical technology. As a result, CGTs almost always require LTFU studies.
Speakers:
- Elizabeth Donahue, senior director, peri-and post-approval studies & real world evidence, PPD clinical research business of Thermo Fisher Scientific
- Luis Pelloso, executive medical director, PPD clinical research business of Thermo Fisher Scientific
- Keith Wonnacott, vice president, regulatory affairs, Lexeo Therapeutics
- Orin Tempkin, global regulatory leader/senior director, Johnson & Johnson Innovative Medicine
- Dan Takefam, principle, Takefam Gene Therapy Advisors LLC
![Screenshot from the webinar "Considerations to optimize and act upon long-term follow-up studies for cell and gene therapies."](https://www.ppd.com/wp-content/uploads/2024/05/cgt-long-term-follow-up-webinar.jpg)
Complete the form to watch the webinar on demand.